Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Webinar series: Modeling NETosis in a Clinically Relevant Environment

Thursday, October 24, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a webinar series focusing on the clinical relevance of H3.1 in severe health conditions like COVID-19 and sepsis. It emphasizes findings from clinical trials conducted in France, the Netherlands, Germany, and the U.S., which indicate a link between elevated H3.1 levels and increased patient severity, particularly in intensive care settings.
Price reaction · baseline $14.19 (2024-10-23 close) · hit pre-market · 5 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Highlights clinical relevance of H3.1 in severe health conditions.
  • Shows correlation between H3.1 levels and patient severity.
  • Involves multiple countries in clinical trials.

Full Press Release Details

Clinical Evidence and Upcoming Studies

This video explores the clinical relevance of H3.1 in severe health conditions, such as COVID-19 and sepsis. We highlight clinical trials in France, the Netherlands, Germany and the U.S. that show a correlation between higher levels of H3.1 with increased patient severity, especially in intensive care.
Click here for the next video in our series: NETosis Induction in Isolated Neutrophils

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the webinar series?

The series focuses on the clinical relevance of H3.1 in severe health conditions.

Which countries are involved in the clinical trials?

The trials are conducted in France, the Netherlands, Germany, and the U.S.

What correlation is highlighted in the article?

It highlights a correlation between higher H3.1 levels and increased patient severity.

What conditions are linked to H3.1 levels?

H3.1 levels are linked to severe conditions like COVID-19 and sepsis.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare H3.1 NETosis COVID-19 sepsis clinical trials
Last updated: Oct 24, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk